Mylan Completes Acquisition Of Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Bus...
`
`Page 1 of 3
`
`News
`Press Releases
`
`Feb 27, 2015
`
`Print
`
`Mylan Completes Acquisition Of Abbott's Non-
`U.S. Developed Markets Specialty And
`Branded Generics Business
`
`POTTERS BAR, England and PITTSBURGH, Feb. 27, 2015 /PRNewswire/ -- Mylan N.V. and Mylan Inc.
`(Nasdaq: MYL) today announced the successful completion of the acquisition of Abbott
`Laboratories' (NYSE: ABT) non-U.S. developed markets specialty and branded generics business.
`
`Executive Chairman Robert J. Coury commented, "Today marks the beginning of the next exciting chapter
`of growth for Mylan. With the completion of this transaction, we will benefit from significantly enhanced
`financial flexibility, an optimized global tax structure and greater balance sheet capacity, all of which position
`us exceptionally well for future opportunities."
`
`Under the previously announced terms of the transaction agreement, Abbott received 110 million shares of
`Mylan N.V., resulting in former Mylan Inc. shareholders now owning approximately 78% of Mylan N.V. and
`Abbott now owning approximately 22% of Mylan N.V. Mylan Inc. and Abbott's non-U.S. developed markets
`specialty and branded generics business have been reorganized under Mylan N.V., a new public company
`organized in the Netherlands. Mylan N.V. will be led by the former Mylan Inc. executive team. The company
`will trade on Nasdaq under the ticker symbol MYL.
`
`Mylan CEO Heather Bresch said, "This transaction significantly enhances our ability to pursue additional
`highly strategic and financially accretive opportunities. These new assets will build upon our exceptional
`existing global platform and the strong growth strategy already in place, and better position our company to
`deliver on our mission of providing the world's seven billion people access to high quality medicine. Not only
`
`http://www.mylan.com/news/press-releases/item?id=123282
`
`NCI Exhibit 2002
`Page 1 of 3
`
`

`
`Mylan Completes Acquisition Of Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Bus...
`
`Page 2 of 3
`
`will this transaction strengthen our financial profile, it will significantly enhance our geographic footprint and
`commercial platform in our largest non-U.S. geographies and create critical mass across our customer sales
`channels.
`
`"Today, we also welcome approximately 3,800 employees from Abbott to Mylan, and we look forward to the
`contributions they will make to our combined organization as they take up our cause of delivering better
`health for a better world."
`
`Forward-Looking Statements
`This press release contains "forward-looking statements." These statements are made pursuant to the safe
`harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements
`may include, without limitation, statements about the acquisition (the "Transaction") by Mylan N.V. ("Mylan")
`of both Mylan Inc. and Abbott Laboratories' non-U.S. developed markets specialty and branded generics
`business (the "Business"), benefits and synergies of the Transaction, future opportunities for Mylan and
`products and any other statements regarding Mylan's future operations, anticipated business levels, future
`earnings, planned activities, anticipated growth, market opportunities, strategies, competition, and other
`expectations and targets for future periods. These may often be identified by the use of words such as "will",
`"may", "could", "should", "would", "project", "believe", "anticipate", "expect", "plan", "estimate", "forecast",
`"potential", "intend", "continue", "target" and variations of these words or comparable words. Because
`forward-looking statements inherently involve risks and uncertainties, actual future results may differ
`materially from those expressed or implied by such forward-looking statements. Factors that could cause or
`contribute to such differences include, but are not limited to: the ability to meet expectations regarding the
`accounting and tax treatments of the Transaction; changes in relevant tax and other laws; the integration of
`the Business being more difficult, time-consuming or costly than expected; operating costs, customer loss
`and business disruption (including, without limitation, difficulties in maintaining relationships with employees,
`customers, clients or suppliers) being greater than expected following the Transaction; the retention of
`certain key employees of the Business being difficult; the possibility that Mylan may be unable to achieve
`expected synergies and operating efficiencies in connection with the Transaction within the expected time
`frames or at all and to successfully integrate the Business; expected or targeted future financial and
`operating performance and results; the capacity to bring new products to market, including but not limited to
`where Mylan uses its business judgment and decides to manufacture, market and/or sell products, directly
`or through third parties, notwithstanding the fact that allegations of patent infringement(s) have not been
`finally resolved by the courts (i.e., an "at-risk launch"); the scope, timing and outcome of any ongoing legal
`proceedings and the impact of any such proceedings on financial condition, results of operations and/or
`cash flows; the ability to protect intellectual property and preserve intellectual property rights; the effect of
`any changes in customer and supplier relationships and customer purchasing patterns; the ability to attract
`and retain key personnel; changes in third-party relationships; the impacts of competition; changes in the
`economic and financial conditions of the business of Mylan; the inherent challenges, risks and costs in
`identifying, acquiring and integrating complementary or strategic acquisitions of other companies, products
`or assets, and in achieving anticipated synergies; uncertainties and matters beyond the control of
`management and inherent uncertainties involved in the estimates and judgments used in the preparation of
`financial statements, and the providing of estimates of financial measures, in accordance with accounting
`principles generally accepted in the United States of America ("U.S. GAAP") and related standards, or on an
`adjusted basis. For more detailed information on the risks and uncertainties associated with Mylan's
`business activities, see the risks described in Mylan Inc.'s Annual Report on Form 10-K for the year ended
`Dec. 31, 2013, as updated by Mylan Inc.'s Current Report on Form 8-K filed on Aug. 6, 2014, Mylan Inc.'s
`
`http://www.mylan.com/news/press-releases/item?id=123282
`
`NCI Exhibit 2002
`Page 2 of 3
`
`

`
`Mylan Completes Acquisition Of Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Bus...
`
`Page 3 of 3
`
`Quarterly Report on Form 10-Q for the period ended June 30, 2014, Mylan Inc.'s Quarterly Report on Form
`10-Q for the period ended Sept. 30, 2014, and Mylan Inc.'s other filings with the Securities and Exchange
`Commission (the "SEC"). These risks, as well as other risks associated with Mylan, the Business and the
`Transaction are also more fully discussed in the Registration Statement on Form S-4 that New Moon B.V.
`(which has been renamed Mylan N.V. and is referred to herein as Mylan) filed with the SEC on Nov. 5, 2014,
`as amended on Dec. 9, 2014, and as further amended on Dec. 23, 2014, and in the proxy statement Mylan
`Inc. filed with the SEC on Dec. 24, 2014, as well as the prospectus Mylan filed with the SEC on Dec. 24,
`2014. You can access Mylan's and Mylan Inc.'s filings with the SEC through the SEC website at
`www.sec.gov, and Mylan strongly encourages you to do so. Mylan undertakes no obligation to update any
`statements herein for revisions or changes after the date of this press release.
`
`Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working
`together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy
`unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact
`the future through passionate global leadership. We offer a growing portfolio of around 1,400 generic
`pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral
`therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also
`operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in
`about 145 countries and territories. Our workforce of approximately 30,000 people is dedicated to creating
`better health for a better world, one person at a time. Learn more at mylan.com.
`
`Logo - http://photos.prnewswire.com/prnh/20140423/77793
`
`To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mylan-
`completes-acquisition-of-abbotts-non-us-developed-markets-specialty-and-branded-generics-business-
`300042793.html
`
`SOURCE Mylan Inc.
`
`Investor
`Company
`
`Recommended for you
`
`More like this
`
`Mylan Confirms First-to-File Patent Challenge
`Relating to NEXAVAR®
`Mylan Confirms First-to-File Patent Challenge
`Relating to NEXAVAR®
`Mylan Signs Exclusive Agreement with Gilead
`Sciences to Distribute Sovaldi® and Harvoni® in
`India
`
`Print
`
`http://www.mylan.com/news/press-releases/item?id=123282
`
`NCI Exhibit 2002
`Page 3 of 3